Praxis Precision Medicines reported a net loss of $83.7 million for the second quarter ended June 30, 2026, compared to $71.1 million in the prior year period. The company held approximately $1.4 billion in cash and investments as of June 30, 2026, providing a runway into 2028. Regulatory updates include successful mid-cycle meetings for ulixacaltamide (PDUFA January 29, 2027) and relutrigine (PDUFA December 27, 2026), with the FDA identifying no major safety or efficacy concerns for either program. Praxis received its third Breakthrough Therapy Designation for elsunersen in SCN2A developmental and epileptic encephalopathies. Commercial launch preparations are accelerating for ulixacaltamide and relutrigine. The company operates as a central nervous system precision neuroscience biopharmaceutical company.
